Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most safety statements (e.g., hepatotoxicity, myelosuppression, nausea/fatigue) are broadly consistent with adverse reactions/precautions, but several claims are not supported or are potentially inaccurate relative to the supplied label excerpts (notably ovarian cancer use and several specificity/wording items such as reversibility of hair loss and 'rare but life-threatening' phrasing).
Category Scores
Accurate Statements
Fatigue is a common side effect of lurbinectedin.
Supported by label adverse reactions: ZEPZELCA + atezolizumab most common includes fatigue/asthenia; single-agent most common includes fatigue.
Nausea and vomiting are common side effects of lurbinectedin.
Label excerpt lists nausea as a most common adverse reaction; 'vomiting' is not explicitly shown in provided excerpts.
Diarrhea is a side effect that can occur with lurbinectedin.
Not supported by the provided label excerpts.
Abdominal pain or discomfort can occur with lurbinectedin.
Not supported by the provided label excerpts.
Lurbinectedin can cause increased liver enzymes.
Single-agent most common adverse reactions include increased alanine aminotransferase.
Regular liver function tests are needed to monitor increased liver enzymes with lurbinectedin.
Label warns hepatotoxicity and states to monitor liver function tests.
Lurbinectedin can decrease white blood cell count.
Single-agent most common adverse reactions include leukopenia/lymphopenia; myelosuppression includes neutropenia.
Decreased white blood cell count from lurbinectedin can make patients more susceptible to infections.
Label indicates severe/fatal myelosuppression including febrile neutropenia and sepsis (supports infection susceptibility concept), though not phrased exactly as 'more susceptible to infections.'
Pulmonary toxicity can occur with lurbinectedin.
Not supported by the provided label excerpts.
Cardiac toxicity can occur with lurbinectedin.
Not supported by the provided label excerpts.
Hematologic toxicity can occur with lurbinectedin.
Label: myelosuppression can cause thrombocytopenia and anemia; also neutropenia/febrile neutropenia.
Hematologic toxicity from lurbinectedin can include anemia, thrombocytopenia, or neutropenia.
Supported: label lists thrombocytopenia and anemia in warnings; adverse reactions include neutropenia and decreased neutrophils.
Unsupported Statements
Lurbinectedin is used to treat relapsed or refractory ovarian cancer.
Ovarian cancer indication is not present in the provided label excerpts.
Lurbinectedin inhibits the transcription of DNA.
Mechanism-of-action transcription inhibition is not provided in the supplied excerpts.
Nausea and vomiting are common side effects of lurbinectedin.
'Vomiting' is not explicitly listed in the provided adverse reaction excerpts (nausea is listed).
Diarrhea is a side effect that can occur with lurbinectedin.
Diarrhea is not listed in the provided adverse reaction excerpts.
Abdominal pain or discomfort can occur with lurbinectedin.
Abdominal pain/discomfort is not listed in the provided adverse reaction excerpts.
Weight loss can occur with lurbinectedin.
Weight loss is not listed in the provided adverse reaction excerpts.
Hair loss can occur with lurbinectedin.
Hair loss is not listed in the provided adverse reaction excerpts.
Hair loss from lurbinectedin is often temporary and reversible once treatment is completed.
No hair loss or reversibility information is present in the provided excerpts.
Lurbinectedin may increase the risk of infections, particularly respiratory tract infections.
While myelosuppression/febrile neutropenia/sepsis are described, 'particularly respiratory tract infections' is not supported by the provided excerpts.
Pulmonary toxicity can occur with lurbinectedin.
Pulmonary toxicity is not mentioned in the provided warnings/adverse reactions excerpts.
Pulmonary toxicity from lurbinectedin is a rare but potentially life-threatening side effect.
Pulmonary toxicity and its 'rare'/'life-threatening' characterization are not present in the provided excerpts.
Cardiac toxicity can occur with lurbinectedin.
Cardiac toxicity is not mentioned in the provided warnings/adverse reaction excerpts.
Cardiac toxicity from lurbinectedin is a rare but potentially life-threatening side effect.
Cardiac toxicity and its 'rare'/'life-threatening' characterization are not present in the provided excerpts.
Regular liver function tests are needed to monitor increased liver enzymes with lurbinectedin.
Partially supported (monitor liver function tests), but the claim ties 'regular' monitoring specifically to 'increased liver enzymes'—label excerpt says 'Monitor liver function tests' without specifying 'regular'.
Contradictions
Low
AI Statement
Lurbinectedin inhibits the transcription of DNA.
Label Reference
No mechanism-of-action transcription inhibition statement is provided in the supplied label excerpts.
Important Omissions
Main approved indication(s in the provided label excerpts are for extensive-stage SCLC maintenance (with/after atezolizumab-based induction) and metastatic SCLC after platinum-based chemotherapy progression; ovarian cancer and relapsed/refractory ovarian cancer are not included.
Importance:
High
No mention of required baseline and monitoring parameters for myelosuppression (ANC ≥ 1,500 cells/mm³ and platelets ≥ 100,000/mm³; monitor blood counts prior to each administration).
Importance:
Moderate
No mention of hepatotoxicity monitoring specifics (withhold/reduce/discontinue based on severity) or other key warnings present in the excerpt (extravasation/tissue necrosis, rhabdomyolysis, embryo-fetal toxicity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Incorrect/unsupported indications (ovarian cancer) and unsupported/over-specific safety claims (pulmonary/cardiac toxicity; reversibility of hair loss; respiratory infection emphasis) could mislead clinical expectations. Some safety/monitoring themes are present but incomplete versus label warnings (e.g., explicit myelosuppression baseline thresholds and other major warnings).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several statements are unsupported by the provided label excerpts, especially an ovarian cancer indication and multiple adverse-effect/toxicity claims (hair loss reversibility; pulmonary/cardiac toxicity; diarrhea/abdominal pain/weight loss; respiratory-infection specificity).
Suggested Improvement
Restrict claims to the provided on-label indications (ES-SCLC maintenance and metastatic SCLC after platinum-based chemotherapy progression) and to adverse reactions/warnings actually present in the label excerpts; avoid adding unlisted toxicities/adverse effects and avoid specific qualifiers (e.g., 'rare but potentially life-threatening', 'often temporary/reversible', 'particularly respiratory tract infections') unless explicitly supported.